Shopping Cart
Remove All
Your shopping cart is currently empty
LYP-IN-4 (compound D14), a reversible and selective lymphotyrosine phosphatase (LYP) inhibitor (Ki=1.34 μM, IC50=3.52μM), regulates TCR signaling, increases PD-1/PD-L1 expression, and strengthens anti-tumor immunity. It also stimulates T cell activation, impedes M2 macrophage polarization, and suppresses tumor progression in MC38 isogenic mouse models.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | LYP-IN-4 (compound D14), a reversible and selective lymphotyrosine phosphatase (LYP) inhibitor (Ki=1.34 μM, IC50=3.52μM), regulates TCR signaling, increases PD-1/PD-L1 expression, and strengthens anti-tumor immunity. It also stimulates T cell activation, impedes M2 macrophage polarization, and suppresses tumor progression in MC38 isogenic mouse models. |
| In vitro | LYP-IN-4 (compound D14) also inhibits other protein tyrosine phosphatases (PTP), with IC50 values of 13.7 μM for PTP1B and 12.3 μM for PTPN1B [1]. |
| In vivo | LYP-IN-4 (compound D14), administered at 25 mg/kg via oral gavage twice daily for 14 consecutive days, significantly inhibited tumor growth and reduced tumor volume in the MC38 genetic model, without affecting mouse body weight [1]. |
| Molecular Weight | 593 |
| Formula | C29H21ClN2O8S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.